Does escitalopram reduce neurotoxicity in major depression?

Journal of Psychiatric Research

Volumn 66-67, Issue , 2015, Pages 118-126

  Halaris, Angelos ^a   Myint, Aye Mu ^b,c   Savant, Vidushi ^a   Meresh, Edwin ^a   Lim, Edwin ^d,e   Guillemin, Gilles ^d   Hoppensteadt, Debra ^a   Fareed, Jawed ^a   Sinacore, James ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b UNIVERSITY OF MUNICH   (Germany)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d MACQUARIE UNIVERSITY   (Australia)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Depression; Escitalopram; Inflammation; Interleukins; Kynurenines; Neurotoxicity; Tryptophan

Indexed keywords

3 HYDROXYKYNURENINE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; ESCITALOPRAM; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; KYNURENIC ACID; KYNURENINE; MONOCYTE CHEMOTACTIC PROTEIN 1; QUINOLINIC ACID; TRYPTOPHAN; TUMOR NECROSIS FACTOR ALPHA; CITALOPRAM; CYTOKINE; INTERLEUKIN DERIVATIVE; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGED; ANTIDEPRESSANT ACTIVITY; ARTICLE; ASSESSMENT OF HUMANS; BECK DEPRESSION INVENTORY; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GUILT; HAMILTON DEPRESSION RATING SCALE; HAMILTON RATING SCALE FOR ANXIETY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR DEPRESSION; MALE; MASS FRAGMENTOGRAPHY; NEUROTOXICITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REMISSION; RESTLESSNESS; WEIGHT REDUCTION; BLOOD; DEPRESSIVE DISORDER, MAJOR; FOLLOW UP; IMMUNOLOGY; PSYCHOLOGICAL RATING SCALE;

ADULT; BIOMARKERS; CITALOPRAM; CYTOKINES; DEPRESSIVE DISORDER, MAJOR; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERLEUKINS; KYNURENINE; MALE; PSYCHIATRIC STATUS RATING SCALES; QUINOLINIC ACID; SEROTONIN UPTAKE INHIBITORS; TRYPTOPHAN;

EID: 84930542962     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2015.04.026     Document Type: Article

References (42)

1. Anisman H., Ravindran A., Griffiths J., Merali Z. Endocrine and cytokine correlates of major depression and dysthymia with typical or atypical features. Mol Psychiatry 1999, 4:182-188.
2. Bender D., McCreanor G. Kynurenine hydroxylase: a potential rate-limiting enzyme in tryptophan metabolism. Biochem Soc Trans 1985, 441-443.
3. Carlin J.M., Borden E.C., Sondel P.M., Byrne G.I. Interferon-induced indoleamine 2,3-dioxygenase activity in human mononuclear phagocytes. JLeukoc Biol 1985, 45:29-34.
4. Carlin J.M., Borden E.C., Sondel P.M., Byrne G.I. Biologic-response-modifier-induced indoleamine 2,3-dioxygenase activity in human peripheral blood mononuclear cell cultures. JImmunol 1987, 139:2414-2418.
5. Chavda N., Kantharia N., Jaykaran Effects of fluoxetine and escitalopram on C-reactive protein in patients of depression. JPharmacol Pharmacother 2011, 2:11-16.
6. Chiarugi A., Calvani M., Meli E., Traggiai E., Moroni F. Synthesis and release of neurotoxic kynurenine metabolites by human monocyte-derived macrophages. JNeuroimmunol 2001, 120:190-198.
7. Connor T.J., Leonard B.E. Depression, stress and immunological activation: the role of cytokines in depressive disorders. Life Sci 1998, 62:583-606.
8. Eller T., Vasar V., Shlik J., Maron E. Pro-inflammatory cytokines and treatment response to escitalopram in major depressive disorder. Prog Neuro-Psychopharmacol Biol Psychiatry 2008, 32:445-450.
9. Haastrup E., Knorr U., Erikstrup C., Kessing L.V., Ullum H. No evidence for an anti-inflammatory effect of escitalopram intervention in healthy individuals with a family history of depression. JNeuroimmunol 2012, 243:69-72.
10. Hannestad J., DellaGioia N., Bloch M. The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacol 2011, 36:2452-2459.
11. Hu B., Hissong B.D., Carlin J.M. Interleukin-1 enhances indoleamine 2, 3-dioxygenase activity by increasing specific mRNA expression in human mononuclear phagocytes. JInterferon Cytokine Res 1995, 15:617-624.
12. Janssen D.G., Caniato R.N., Verster J.C. Apsychoneuroimmunological review on cytokines involved in antidepressant treatment response. Hum Psychopharmacol 2010, 25:201-215.
13. Kaestner F., Hettich M., Peters M., Sibrowski W., Hetzel G., Ponath G., et al. Different activation patterns of proinflammatory cytokines in melancholic and non-melancholic major depression are associated with HPA axis activity. JAffect Disord 2005, 87:305-311.
14. Kennedy S.H., Andersen H.F., Lam R.W. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. Rev Psychiatr Neurosci 2006, 31(2):122-131.
15. Kennedy S.H., Andersen H.F., Thase M.E. Escitalopram in the treatment of major depressive disorder: a meta-analysis. Curr Med Res Opin 2009, 25:161-175.
16. Kim Y., Suh I., Kim H., Han C., Lim C., Choi S., et al. The plasma levels of interleukin-12 in schizophrenia, major depression, and bipolar mania: effects of psychotropic drugs. Mol Psychiatry 2002, 7:1107.
17. Kirino E. Escitalopram for the management of major depressive disorder: a review of its efficacy, safety, and patient acceptability. Patient Prefer Adher 2012, 6:853-861.
18. Kocki T., Wnuk S., Kloc R., Kocki J., Owe-Larsson B., Urbanska E.M. New insight into the antidepressants action: modulation of kynurenine pathway by increasing the kynurenic acid/3-hydroxykynurenine ratio. JNeural Transm 2012, 119:235-243.
19. Krause D.L., Riedel M., Müller N., Weidinger E., Schwarz M.J., Myint A. Effects of antidepressants and cyclooxygenase-2 inhibitor on cytokines and kynurenines in stimulated invitro blood culture from depressed patients. Inflammopharmacology 2012, 20:169-176.
20. Lalit V., Appaya P.M., Hegde R.P., Mital A.K., Mittal S., Nagpal R., et al. Escitalopram versus citalopram and sertraline: a double-blind controlled, multi-centric trial in Indian patients with unipolar major depression. Indian J Psychiatry 2004, 46:333-341.
21. Lanquillon S., Krieg J., Bening-Abu-Shach U., Vedder H. Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology 2000, 22:370-379.
22. Lapin I.P., Oxenkrug G.F. Intensification of the central serotoninergic processes as a possible determinant of the thymoleptic effect. Lancet 1969, 293:132-136.
23. Lorca P.M., Fernandez J.L. Escitalopram in the treatment of major depressive disorder: clinical efficacy, tolerability and cost-effectiveness vs venlafaxine extended-release formulation. Int J Clin Pract 2007, 61(4):702-710.
24. Mikova O., Yakimova R., Bosmans E., Kenis G., Maes M. Increased serum tumor necrosis factor alpha concentrations in major depression and multiple sclerosis. Eur Neuropsychopharmacol 2001, 11:203-208.
25. Montgomery S., Hansen T., Kasper S. Efficacy of escitalopram compared to citalopram: a meta-analysis. Int J Neuropsychopharmacol 2011, 14:261-268.
26. Moore N., Verdoux H., Fantino B. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol 2005, 20:131-137.
27. Musso T., Gusella G., Brooks A., Longo D., Varesio L. Interleukin-4 inhibits indoleamine 2,3-dioxygenase expression in human monocytes. Blood 1994, 83:1408-1411.
28. Myint A.M. Kynurenines: from the perspective of major psychiatric disorders. FEBS J 2012, 279:1375-1385.
29. Myint A.M., Kim Y.K. Cytokine-serotonin interaction through IDO: a neurodegeneration hypothesis of depression. Med Hypotheses 2003, 61:519-525.
30. Myint A., Kim Y. Network beyond IDO in psychiatric disorders: revisiting neurodegeneration hypothesis. Prog Neuro-Psychopharmacol Biol Psychiatry 2014, 48:304-313.
31. Myint A., Leonard B.E., Steinbusch H.W.M., Kim Y. Th1, Th2, and Th3 cytokine alterations in major depression. JAffect Disord 2005, 88:167-173.
32. Myint A., Kim Y.K., Verkerk R., Scharpé S., Steinbusch H., Leonard B. Kynurenine pathway in major depression: evidence of impaired neuroprotection. JAffect Disord 2007, 98:143-151.
33. Oades R.D., Dauvermann M.R., Schimmelmann B.G., Schwarz M.J., Myint A. Research attention-deficit hyperactivity disorder (ADHD) and glial integrity: S100B, cytokines and kynurenine metabolism-effects of medication. Behav Brain Funct 2010, 6:29.
34. Ou J., Xun G., Wu R., Li L., Fang M., Zhang H., et al. Efficacy and safety of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, randomized, double-blind, flexible-dose study. Psychopharmacology 2011, 213:639-646.
35. Perkins M.N., Stone T.W. An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid. Brain Res 1982, 247:184-187.
36. Piletz J.E., Halaris A., Iqbal O., Hoppensteadt D., Fareed J., Zhu H., et al. Pro-inflammatory biomarkers in depression: treatment with venlafaxine. World J Biol Psychiatry 2009, 10:313-323.
37. Smythe G.A., Braga O., Brew B.J., Grant R.S., Guillemin G.J., Kerr S.J., et al. Concurrent quantification of quinolinic, picolinic, and nicotinic acids using electron-capture negative-ion gas chromatography-mass spectrometry. Anal Biochem 2002, 301:21-26.
38. Taylor M.W., Feng G.S. Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. Faseb J 1991, 5:2516-2522.
39. Thomas A.J., Davis S., Morris C., Jackson E., Harrison R., O'Brien J. Increase in interleukin-1beta in late-life depression. Am J Psychiatry 2005, 162:175-177.
40. Yasui H., Takai K., Yoshida R., Hayaishi O. Interferon enhances tryptophan metabolism by inducing pulmonary indoleamine 2, 3-dioxygenase: its possible occurrence in cancer patients. Proc Natl Acad Sci 1986, 83:6622-6626.
41. Yevtushenko V.Y., Belous A.I., Yevtushenko Y.G., Gusinin S.E., Buzik O.J., Agibalova T.V. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients. Clin Ther 2007, 29:2319-2332.
42. Zunszain P.A., Anacker C., Cattaneo A., Choudhury S., Musaelyan K., Myint A.M., et al. Interleukin-1β: a new regulator of the kynurenine pathway affecting human hippocampal neurogenesis. Neuropsychopharmacology 2012, 37:939-949.